Piramal Pharma Limited
PPLPHARMA · NSE · ₹198 a share (close of 01 Oct 2026)
Available company data, source links and archived checks for Piramal Pharma Limited. Read each source and date: a past check is not a fresh review, and some earlier figures have incomplete source details.
Revenue rose 17.4%; Net loss was ₹69.39 crore.
Quarter ended 2026-06-30 · consolidated · Company filing
Recorded quarterly figures
| Quarter | Revenue / income | YoY |
Profit | YoY | Net margin | Source |
|---|
| Jun 2026 | Revenue: ₹2,270 cr | +17.4% | Net profit: ₹-69 cr | — | -3.1% | Company filing source |
| Mar 2026 | Revenue: ₹2,752 cr | -0.1% | Net profit: ₹-9 cr | -105.7% | -0.3% | Company filing source |
| Dec 2025 | Revenue: ₹2,140 cr | — | Net profit: ₹-136 cr | — | -6.4% | Company filing source |
| Sep 2025 | Revenue: ₹2,044 cr | — | Net profit: ₹-99 cr | — | -4.9% | Company filing source |
| Jun 2025 | Revenue: ₹1,934 cr | -0.9% | Net profit: ₹-82 cr | — | -4.2% | Company filing source |
| Mar 2025 | Revenue: ₹2,754 cr | — | Net profit: ₹154 cr | — | 5.6% | Company filing source |
YoY means change from the same quarter a year earlier.
— means no comparable figure is available. Older entries with incomplete source
details have not been revalidated under the current checks.
Who holds it — from the filings
The Sri Krishna Trust (through its Trustee Mr. Ajay G Piramal and Dr. (Mrs.) Swati A. Piramal) 26.5%CA Alchemy Investments 17.9%Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund 7.7%V3 Designs LLP 3.2%PRL Realtors LLP 3.0%register as filed
2026-06-30
Filing timeline — what the company told the exchange
- Change in Management. Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regula…
30 Sep 2026 · document
- Change in Management. Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regula…
30 Sep 2026 · document
- News Verification. The Exchange has sought clarification from Piramal Pharma Limited with respect to recent news item captioned Ontario Contributes $1.7 Million…
30 Sep 2026 · document
- Piramal Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015…
29 Sep 2026 · document
- Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company. Disclosure under Regulation 30 of Securities and Exchange Board of India(Listing Obli…
29 Sep 2026 · document
- General Updates. Disclosure under Regulation 30 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 ESG…
18 Sep 2026 · document
- General Updates. Disclosure under Regulation 30 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015 FDA…
14 Sep 2026 · document
- Analysts/Institutional Investor Meet/Con. Call Updates. Intimation of Schedule of Institutional Investor Meetings under the SEBI (Listing Obligations and Disclo…
08 Sep 2026 · document
Follow this company without reading every document yourself.
Keep its available filings, dated fact checks and disclosure alerts together.
Your saved country sets your market and its research schedule.
Start free — first week on us →
India ₹149/month · Rest of world US$4.99/month after the free trial · research, not investment
advice · cancel any time